Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658701 | 1.00 | GCK (0.47) | GCKKCNH2FFAR2SMN1; SMN2 | |
| SCHEMBL3863088 | 1.00 | GCK (0.47) | GCKKCNH2FFAR2SMN1; SMN2 | |
| SCHEMBL2647175 | 1.00 | GCK (0.47) | GCKKCNH2FFAR2SMN1; SMN2 | |
| SCHEMBL2646555 | 0.92 | SMN1; SMN2 (0.54) | GCKKCNH2SMN1; SMN2 | |
| SCHEMBL2658507 | 0.90 | GCK (0.47) | GCKKCNH2FFAR2 | |
| SCHEMBL2645667 | 0.90 | FFAR2 (0.57) | GCKKCNH2FFAR2SMN1; SMN2 | |
| SCHEMBL2647051 | 0.90 | GCK (0.47) | GCKKCNH2FFAR2 | |
| SCHEMBL2646174 | 0.89 | GCK (0.47) | GCKKCNH2FFAR2 | |
| SCHEMBL2658530 | 0.88 | L3MBTL1 (0.46) | GCKKCNH2FFAR2SMN1; SMN2 | |
| SCHEMBL2644873 | 0.88 | L3MBTL1 (0.46) | GCKKCNH2FFAR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534593-B2 | Crystals of glucokinase and methods of growing them | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | claimed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | claimed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | claimed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | claimed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | claimed |
| US-7534593-B2 | Crystals of glucokinase and methods of growing them | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060141599-A1 | Crystals of Glucokinase and methods of growing them | CORBETT WENDY L | 2006-06-29 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6911545-B2 | Crystals of glucokinase and methods of growing them | HOFFMAN-LA ROCHE INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-20030219887-A1 | Crystals of glucokinase and methods of growing them | HOFFMANN-LA ROCHE INC. | 2003-11-27 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885KCNH2 1022/4885FFAR2 1513/4885 |
| US-20030219887-A1 | Crystals of glucokinase and methods of growing them | GCK, GCKR, GALK1 | GCK 1/4885KCNH2 1294/4885FFAR2 3196/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885KCNH2 1062/4885FFAR2 1419/4885 |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885KCNH2 1022/4885FFAR2 1513/4885 |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | GCK 2/4885KCNH2 1022/4885FFAR2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.